pipe-307
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 26, 2021 (NCT04725175)
Timeline
Indications
Mechanism of action
- Muscarinic acetylcholine receptor M1INHIBITOR
CHRM1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06083753 | Phase 2 | Nov 6, 2023 | Pipeline Therapeutics, Inc. |
| NCT04941781 | Phase 1 | Sep 1, 2021 | Pipeline Therapeutics, Inc. |
| NCT04725175 | Phase 1 | Feb 26, 2021 | Pipeline Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pipeline Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1